Core Viewpoint - The new healthcare policy aims to enhance the accessibility of innovative drugs through the establishment of a commercial insurance innovation drug directory, which is expected to include around 20 to 30 new drugs, thereby improving the overall insurance coverage for patients [6][9]. Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) has released a series of documents outlining the adjustments to the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug directories, as well as the commercial health insurance innovation drug directory [2][4]. - The new policy emphasizes a collaborative negotiation mechanism for the commercial insurance innovation drug directory, differing from the basic insurance directory's negotiation process [6][8]. Group 2: Market Impact - The introduction of the commercial insurance innovation drug directory is expected to allow insurance companies to negotiate prices with pharmaceutical companies, leading to lower prices compared to existing market rates [6][8]. - This policy is anticipated to expand the coverage of commercial insurance and reduce operational costs for insurance companies, ultimately benefiting patients by increasing their access to innovative drugs [6][9]. Group 3: Implementation and Future Outlook - The NHSA will begin accepting applications from eligible companies for the new drug directory starting from July 20, 2023, indicating that the preparation for the 2025 adjustments is nearly complete [9]. - The dynamic nature of the directory, which will be updated annually, suggests that more innovative drugs may be included in short-term health insurance plans in the future, providing more options for the public [8][9].

Core Insights - The National Healthcare Security Administration (NHSA) has released a new policy framework for the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as the commercial health insurance innovative drug catalog [1][2] - The new policy signals a shift towards a collaborative pricing mechanism for innovative drugs, allowing commercial insurance companies to negotiate prices with pharmaceutical firms, which is expected to lower costs and expand coverage [2][3] Group 1: Policy Design and Market Impact - The newly introduced commercial insurance innovative drug catalog is expected to include around 20 to 30 drugs, filling gaps in the basic medical insurance catalog and enhancing overall coverage [1] - The commercial insurance innovative drug catalog emphasizes a negotiation mechanism, differing from the basic medical insurance catalog's negotiation process, indicating a more flexible approach to pricing [1][2] - The policy aims to benefit the public by increasing access to new and effective medications, allowing patients to enjoy greater reimbursement for innovative drugs [2] Group 2: Role of Commercial Insurance Companies - Commercial insurance companies will have the opportunity to negotiate prices with pharmaceutical companies, which is a significant shift from previous practices where they had limited bargaining power [2] - Different insurance companies will design various insurance products based on their payment capabilities, leading to a competitive environment and broader coverage options for consumers [2][3] - The NHSA will selectively invite experienced commercial insurance companies to participate in the negotiation process, ensuring that their input is considered in the final decisions [2] Group 3: Future Implications for Innovative Drugs - The dynamic nature of the drug catalog, which will be adjusted annually, suggests that more innovative drugs may be included in short-term health insurance plans, providing consumers with more choices [3] - Pharmaceutical companies can apply for inclusion in the commercial insurance innovative drug catalog independently or alongside the basic catalog, enhancing their market opportunities [3] - The integration of the basic drug catalog with the commercial insurance innovative drug catalog will be strengthened, impacting how drugs are priced, demanded, and reimbursed in the market [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.30%, outperforming the CSI 300 index which rose by 3.52% during the reporting period [3][14] - The PE ratio (TTM, excluding negative values) for the pharmaceutical and biotechnology industry as of July 4, 2025, is 28.52x, up from 27.28x in the previous period, indicating an upward trend in valuation [3][19] - Notable sub-industries include "Other Biological Products" and "Medical R&D Outsourcing," which saw increases of 11.20% and 9.37% respectively, while "Medical Equipment" and "Blood Products" lagged with increases of only 0.98% [3][14] Industry Trends - The report highlights significant policy measures from the National Healthcare Security Administration and the National Health Commission aimed at supporting the high-quality development of innovative drugs [5][6] - The introduction of a commercial health insurance innovative drug directory is a key breakthrough, facilitating better pricing and reimbursement mechanisms for high-value drugs [6] - The report emphasizes the importance of the innovative drug industry chain, particularly focusing on platform pharmaceutical companies, clinical CROs, and high-barrier CDMOs [6] Important Industry News - The approval of several innovative drugs, including "ZEGFROVY" by Dize Pharmaceutical and "TQG203" by Zhengda Tianqing, marks significant advancements in the industry [41][42][46] - The report notes that the global number of hemophilia patients is expected to increase by 25% by 2025, highlighting the growing market for innovative treatments [42] - The approval of "Mastrudep" by Innovent Biologics for weight management in adults showcases the expanding therapeutic applications of GLP-1R/GCGR dual agonists [49][50] Investment Recommendations - Continuous attention is recommended for the innovative drug industry chain, particularly for companies that can navigate the new dual directory system and have international expansion capabilities [6] - The report suggests that the recent policy changes and the successful IPO of a biotech company signal a positive outlook for the innovative drug sector [6]

Group 1: US-China Trade Relations - The US has lifted export restrictions on EDA software, ethane, and aircraft engines to China, following recent trade talks [1] - The Chinese Ministry of Commerce confirmed that both sides are working to implement the consensus reached during the June 5 call between the two countries' leaders [1][2] - The lifting of restrictions is seen as a positive signal for further cooperation and outcomes in US-China trade relations [2] Group 2: National Unified Market Construction - The Central Economic Commission of China has emphasized the need to deepen the construction of a national unified market, focusing on "five unifications and one openness" [3] - Specific measures include addressing low-price disorderly competition and promoting the integration of domestic and foreign trade [3][4] - The strategic upgrade reflects a shift from internal integration to external collaboration, aiming for long-term high-quality development [4] Group 3: Health Insurance and Innovative Drugs - The National Healthcare Security Administration has introduced measures to support the development of innovative drugs, including the establishment of a commercial health insurance directory for innovative drugs [5][6] - This directory will include high-value innovative drugs that exceed basic medical insurance coverage, alleviating pressure on the medical insurance fund [6] - The initiative aims to create a sustainable payment pathway for high-value innovative drugs while ensuring basic medical insurance focuses on essential coverage [6] Group 4: Foreign Investment Tax Incentives - The Chinese government has announced a tax credit policy for foreign investors reinvesting profits in domestic projects, effective from January 1, 2025, to December 31, 2028 [7] - This policy aims to encourage foreign investment by allowing a 10% tax credit on reinvested profits, which is a significant incentive compared to previous policies [7] - The move is part of broader efforts to stabilize foreign investment amid declining actual foreign capital usage in China [7] Group 5: Solar Industry Regulation - The Ministry of Industry and Information Technology has convened a meeting with 14 solar companies to address low-price competition in the solar industry [8][9] - The government aims to enhance product quality and facilitate the orderly exit of outdated production capacity to promote sustainable development [8] - The recent actions signal a strong commitment from the highest levels of government to tackle the issue of unhealthy competition in the solar sector [9] Group 6: Major Infrastructure Projects - The National Development and Reform Commission has allocated over 300 billion yuan to support the third batch of "two heavy" construction projects for 2025, totaling 800 billion yuan for the year [10][11] - These projects focus on critical areas such as ecological restoration, transportation infrastructure, and urban underground networks [10] - The coordinated fiscal and monetary policies aim to provide sufficient funding for these major projects, which are crucial for stabilizing investment growth [11] Group 7: Manufacturing Sector Performance - The manufacturing PMI for June rose to 49.7%, indicating a slight improvement in manufacturing activity, with production and new orders both showing positive trends [12][13] - Despite the increase, the PMI remains below the 50% threshold, suggesting that the recovery in the manufacturing sector is still fragile [12][13] - External uncertainties and fluctuating demand continue to pose challenges for the manufacturing industry, necessitating supportive macroeconomic policies [13] Group 8: US Tax and Spending Legislation - The US Congress has passed the "Big and Beautiful" tax and spending bill, which includes significant tax cuts and is expected to increase the federal deficit by approximately $3.3 trillion over the next decade [14][15] - The legislation has raised concerns among investors regarding its long-term fiscal implications, including potential cuts to federal assistance and increased national debt [14][15] - The market's reaction indicates growing apprehension about the sustainability of US fiscal policies and their impact on global investment strategies [15]

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, WuXi AppTec, Asymchem Laboratories, Hangzhou Tigermed Consulting, and APT Medical [6][32] - The report also maintains an "Outperform" rating for H-Shares including PATEO, Hansoh Pharmaceutical Group, Innovent Biologics, WuXi XDC Cayman, Luye Pharma Group, and BeiGene [6][32] Core Insights - The commercial insurance innovative drug list is expected to be released soon, which is anticipated to improve the domestic market significantly [33] - The National Healthcare Security Administration and National Health Commission have released measures to support the high-quality development of innovative drugs, focusing on high-innovation drugs with significant clinical value [33] - The pharmaceutical sector underperformed the market in June 2025, with the Shanghai Composite Index rising by 2.9% while the SW Pharma Bio index rose by only 0.7% [34] - The Hang Seng Healthcare sector outperformed the market with an increase of 8.4% in June 2025, while the U.S. S&P Healthcare Select Sector underperformed with a rise of only 1.9% [35] Summary by Sections - **Investment Highlights**: Continuous positive outlook for innovative drugs and industry chain, with specific A-Shares and H-Shares recommended for investment [32][6] - **Market Performance**: In June 2025, the pharmaceutical sector's performance was weak compared to the overall market, ranking 19th among Shenwan primary industries [34] - **Sub-sector Analysis**: The best-performing sub-sectors included medical services (+4.8%), chemical preparations (+0.8%), and chemical raw materials (+0.5%) [34][20] - **Stock Performance**: Top gainers in the pharmaceutical sector included Zhejiang Anglikang Pharmaceutical (+146.4%) and Hubei Huaqiang High-Tech Co., Ltd. (+67.4%), while top losers included Kexing Biopharm Co., Ltd. (-28.7%) [34][23]

Core Viewpoint - The pharmaceutical and biotechnology industry is experiencing moderate performance, with the introduction of the commercial insurance innovative drug catalog and the deepening application of artificial intelligence in healthcare presenting structural opportunities for growth [1][3]. Group 1: Commercial Insurance Innovative Drug Catalog - The National Healthcare Security Administration and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, establishing a commercial insurance innovative drug catalog that focuses on innovative drugs with significant clinical value but outside the scope of medical insurance [1]. - The catalog aims to eliminate barriers for high-value innovative drugs through a "three exclusions" policy, which does not count towards the self-pay rate of medical insurance, monitors alternative products, and limits payment by disease type [1]. - The actual effectiveness of the catalog depends on the payment capabilities of commercial insurance and the collaboration with medical institutions, with the current payment proportion for innovative drugs being less than 8%, while the policy aims to increase this to 44% over the next decade [1][2]. Group 2: AI in Healthcare - Artificial intelligence is rapidly penetrating the entire pharmaceutical industry chain, significantly shortening drug development cycles and reducing costs through target screening, molecular design, and clinical trial optimization [3]. - The National Science and Technology Major Project has allocated 1.75 billion yuan for AI-assisted new drug development projects, focusing on breakthroughs in infectious diseases and rare diseases by 2025 [3]. - The intelligent transformation of medical services is also accelerating, with AI-assisted diagnostic systems becoming more mature in applications such as imaging recognition and pathological analysis [3]. - Despite optimism about the long-term potential of AI technology, challenges such as data fragmentation, privacy protection, and the lack of interpretability of AI models remain significant barriers to large-scale application [3].

7月1日，在《支持创新药高质量发展的若干措施》发布之后，国家医保局发布《2025年国家基本医疗保 险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案（征求意见稿）》（以下 简称《工作方案》）等文件，向社会公开征求意见。公众可于2025年7月7日（星期一）17:00前提出意 见和建议。 这意味着2025年的国谈即将到来。而与往年不同的是，今年商业健康保险创新药品目录（以下简称"商 保创新药目录"）也将同步启动申报，重点纳入创新程度高、临床价值大、患者获益显著且超出基本医 保保障范围的创新药，推荐商业健康保险、医疗互助等多层次医疗保障体系参考使用。 上海市卫生和健康发展研究中心主任金春林向21世纪经济报道记者表示，与往年相比，今年的目录调整 有诸多不同，首先，今年增设商保创新药目录后，企业就有了两种选择，对创新药的发展具有重要的推 动作用；其次，今年评审所需的材料全部由线上提交，这样对材料的准确性要求也更强了；再次，今年 也更强调差异化，也就是除了真创新之外，药品是否能够满足差异化的临床需求，这是很加分的一项。 "此外，当前医保资金持续'紧平衡'，再加上有较多的新药上市，所以从医保资金总量来看， ...

Core Insights - The establishment of the Commercial Health Insurance Innovative Drug Directory (referred to as "Commercial Drug Directory") is a significant change aimed at clarifying the boundaries of basic medical insurance and providing more development space for commercial health insurance [1][2]. Group 1: Policy Changes - The new measures introduced by the National Healthcare Security Administration and the National Health Commission emphasize the need for a multi-tiered medical security system, which includes the Commercial Drug Directory focusing on high-innovation, clinically valuable drugs that exceed basic insurance coverage [1][2]. - The Commercial Drug Directory will not be included in the self-pay rate indicators of basic medical insurance or monitored for alternative products in centralized procurement [1][3]. Group 2: Market Opportunities - The introduction of the Commercial Drug Directory is expected to expand the "coverage boundary" for commercial health insurance, allowing it to evolve from merely supplementing basic insurance to independently covering innovative drugs [2][4]. - The commercial health insurance sector is projected to see significant growth, with the total compensation for innovative drugs reaching 12.4 billion yuan, reflecting a compound annual growth rate of 103% over the past three years [4]. Group 3: Industry Dynamics - The shift from a directory nature to a "recommended list" for the Commercial Drug Directory indicates that commercial insurance companies may no longer directly participate in the directory formulation, which could lead to the cancellation of intended price negotiations [3][4]. - The new policy encourages commercial health insurance to expand its investment in innovative drugs, potentially creating a stable long-term investment environment for drug development [6][5]. Group 4: Future Directions - The measures aim to enhance the integration of basic medical insurance and commercial health insurance, creating a collaborative effort to support public health and provide economic backing for innovative drugs [5][6]. - The commercial health insurance industry is encouraged to explore new product directions, such as outpatient coverage and digital health management, to transition from a "cost reimbursement" model to a "health value" model [5][6].

Group 1 - The core viewpoint of the news is the release of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission, which includes 16 initiatives aimed at supporting the entire chain of innovative drug development, access, and payment [1][2] - The measures emphasize the importance of supporting innovative drugs to go global, encouraging regions to explore building global trading platforms for innovative drugs, particularly targeting Southeast Asia, Central Asia, and other Belt and Road countries [1][5] - The new "1+" drug approval mechanism in Hong Kong, effective from November 2023, aims to streamline the registration process for innovative drugs, allowing for faster market entry and enhancing Hong Kong's role as a bridge for innovative drugs to reach global markets [7][8] Group 2 - The establishment of a commercial health insurance innovative drug directory is a significant highlight of the measures, which will include innovative drugs that exceed basic insurance coverage and have high clinical value [3][4] - The commercial health insurance innovative drug directory will be developed by the National Medical Insurance Administration, allowing companies to apply for inclusion in either the insurance directory or the basic medical insurance directory [3][4] - The measures also aim to enhance the multi-layered payment capabilities for innovative drugs, addressing the challenges of price expectations from innovative drug companies and the payment capabilities of insurance [2][3] Group 3 - The measures propose to support the expansion of investment in innovative drugs by commercial health insurance, fostering a patient capital environment for innovative drug companies [5][6] - The collaboration between Hong Kong and Shenzhen aims to establish a "Real-World Research and Application Center" to promote data sharing and expedite drug approval processes [6][8] - The National Medical Insurance Administration plans to implement more effective measures to support the pricing of innovative drugs going abroad, including exploring stricter price confidentiality mechanisms for drugs in the commercial health insurance directory [10]

Group 1 - The establishment of a "Commercial Health Insurance Innovative Drug Directory" aims to address the payment challenges for high-priced innovative drugs outside of basic medical insurance [1][2][3] - The new policy signals a shift in the role of commercial insurance in supporting innovative drug payments, creating a multi-tiered medical security system [2][4] - The commercial health insurance sector is expected to develop specialized insurance products to support innovative drug payments, leveraging standardized drug lists and pricing mechanisms [3][4] Group 2 - The current basic medical insurance system has limitations in funding, particularly for high-cost treatments like CAR-T therapy, which can exceed one million yuan [4][5] - Commercial health insurance has a small market share in innovative drug payments, with only 7.7% of the innovative drug market being covered by commercial health insurance expenditures [5][6] - The "Hui Min Bao" program has made significant contributions to innovative drug payments, but its compensation for innovative drugs remains low compared to the overall market size [6][5] Group 3 - The implementation of the new policy presents challenges for insurance companies, including directory management, payment negotiations, cost impacts, risk control, and market education [7][8] - A robust evaluation system is necessary for assessing the clinical value and cost-effectiveness of innovative drugs, which poses a significant challenge for insurers [7][8] - The lack of historical data and the need for effective risk management strategies complicate the pricing and compensation models for innovative drugs [9][10] Group 4 - Data sharing between basic medical insurance and commercial health insurance is crucial for enhancing the effectiveness of innovative drug payment systems [11][13] - The development of specialized data interfaces and standardized coding for diseases and drugs is recommended to facilitate better collaboration between insurance sectors [14][13] - The focus on improving data collaboration can lead to more precise product development and risk management in the commercial health insurance market [13][14]